Salarius Pharmaceuticals, Inc. financial data

Symbol
SLRX on Nasdaq
Location
2450 Holcombe Blvd, Suite J 608, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 189 % +446%
Return On Equity -556 % -274%
Return On Assets -192 % -74.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.65M shares +431%
Common Stock, Shares, Outstanding 2.13M shares +232%
Entity Public Float 1.5M USD -69.5%
Common Stock, Value, Issued 213 USD +233%
Weighted Average Number of Shares Outstanding, Basic 2.12M shares +254%
Weighted Average Number of Shares Outstanding, Diluted 2.12M shares +254%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 504K USD -67.5%
General and Administrative Expense 4.67M USD -9.89%
Operating Income (Loss) -5.18M USD +23.2%
Net Income (Loss) Attributable to Parent -5.1M USD +21.1%
Earnings Per Share, Basic -1 USD/shares +92.8%
Earnings Per Share, Diluted -1 USD/shares +92.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 795K USD -75.7%
Other Assets, Current 26.5K USD -82.5%
Assets, Current 1.36M USD -61.3%
Other Assets, Noncurrent 33.2K USD -16.9%
Assets 1.39M USD -60.8%
Accounts Payable, Current 1.48M USD +130%
Liabilities 2.22M USD +88.6%
Retained Earnings (Accumulated Deficit) -84.6M USD -6.42%
Stockholders' Equity Attributable to Parent -830K USD -135%
Liabilities and Equity 1.39M USD -60.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.18M USD +12.7%
Net Cash Provided by (Used in) Financing Activities 546K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 2.13M shares +232%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -636K USD +58.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 795K USD -75.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.09K USD +1.87%
Deferred Tax Assets, Valuation Allowance 17.1M USD +7.54%
Deferred Tax Assets, Gross 17.1M USD +7.54%
Deferred Tax Assets, Operating Loss Carryforwards 8.35M USD +35.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 83.8M USD +2.32%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.11K USD -0.09%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%